Antoinette Tan, MD
Medical Oncology · Charlotte, NCNPI 1982781738
Payments from drug & device makers
Across 423 payments — averaging $35,188 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$8.6M
- Merck$3.1M
- Roche Products Limited$878K
- Genentech, Inc.$494K
- Hoffmann-la Roche Limited$493K
- GSK$413K
- plus $980K from 19 others
Across 9 payments — averaging $914.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 92 | $8,562,090 |
| Merck | 15 | $3,064,037 |
| Roche Products Limited | 4 | $877,994 |
| Genentech, Inc. | 66 | $494,095 |
| Hoffmann-la Roche Limited | 27 | $493,436 |
| GSK | 39 | $412,652 |
| Daiichi Sankyo Inc. | 15 | $354,710 |
| Tesaro, Inc. | 22 | $274,913 |
| AstraZeneca | 9 | $167,558 |
| Deciphera Pharmaceuticals Inc. | 60 | $39,142 |
| Novartis | 12 | $35,136 |
| G1 Therapeutics, Inc. | 6 | $34,674 |
| Immunogen, Inc. | 1 | $17,000 |
| Genentech USA, Inc. | 12 | $13,293 |
| Jazz Pharmaceuticals Inc. | 4 | $11,580 |
| Stemline Therapeutics Inc. | 6 | $10,233 |
| Eli Lilly | 2 | $4,800 |
| Bristol Myers Squibb | 6 | $4,554 |
| AbbVie | 12 | $4,492 |
| Eisai Inc. | 1 | $3,375 |
| Athenex Pharmaceutical Division, LLC | 5 | $2,107 |
| Seagen Inc. | 1 | $1,380 |
| F. Hoffmann-la Roche AG | 2 | $1,107 |
| Caris MPI, Inc. | 2 | $267 |
| Gilead | 2 | $61 |
How this compares
$14,884,685 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Charlotte
- Nilanjan GhoshCharlotte$6.3M
- Kathryn MilehamCharlotte$4.7M
- David RizzieriCharlotte$1.8M
- Edward KimCharlotte$1.7M
- Jimmy HwangCharlotte$1.3M
- Kimberly StricklandCharlotte$1.1M
- Obiageli OgbataCharlotte$861K
- Daniel CarrizosaCharlotte$827K
- Mohamed SalemCharlotte$658K
- Ashley SumrallCharlotte$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.